Ten-Year Outcomes: The Clinical Utility of Single Photon Emission Computed Tomography/Computed Tomography Capromab Pendetide (Prostascint) in a Cohort Diagnosed With Localized Prostate Cancer

Ellis, Rodney J.; Kaminsky, Deborah A.; Zhou, Esther H.; Fu, Pingfu; Chen, Wei Dong; Brelin, Alaina M.; Faulhaber, Peter; Bodner, Donald R.

doi:10.1016/j.ijrobp.2010.05.053

Cited by 30 publications

(17 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Outcome from the first analysis is shown in Figs 1–3 and represents the PSA progression‐free survival outcomes by treatment modality for low‐, intermediate‐ and high‐risk groups [4–69]. In low‐risk patients, higher average PSA progression‐free survival was reported for brachytherapy than for RP or EBRT.…”

Section: Resultsmentioning

confidence: 99%

Comparative analysis of prostate‐specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group

Billiet²,

et al. 2012

View full text Add to dashboard Cite

What's known on the subject? and What does the study add? Very few comparative studies to date evaluate the results of treatment options for prostate cancer using the most sensitive measurement tools. PSA has been identified as the most sensitive tool for measuring treatment effectiveness. To date, comprehensive unbiased reviews of all the current literature are limited for prostate cancer. This is the first large scale comprehensive review of the literature comparing risk stratified patients by treatment option and with long‐term follow‐up. The results of the studies are weighted, respecting the impact of larger studies on overall results. The study identified a lack of uniformity in reporting results amongst institutions and centres. A large number of studies have been conducted on the primary therapy of prostate cancer but very few randomized controlled trials have been conducted. The comparison of outcomes from individual studies involving surgery (radical prostatectomy or robotic radical prostatectomy), external beam radiation (EBRT) (conformal, intensity modulated radiotherapy, protons), brachytherapy, cryotherapy or high intensity focused ultrasound remains problematic due to the non‐uniformity of reporting results and the use of varied disease outcome endpoints. Technical advances in these treatments have also made long‐term comparisons difficult. The Prostate Cancer Results Study Group was formed to evaluate the comparative effectiveness of prostate cancer treatments. This international group conducted a comprehensive literature review to identify all studies involving treatment of localized prostate cancer published during 2000–2010. Over 18 000 papers were identified and a further selection was made based on the following key criteria: minimum/median follow‐up of 5 years; stratification into low‐, intermediate‐ and high‐risk groups; clinical and pathological staging; accepted standard definitions for prostate‐specific antigen failure; minimum patient number of 100 in each risk group (50 for high‐risk group). A statistical analysis (standard deviational ellipse) of the study outcomes suggested that, in terms of biochemical‐free progression, brachytherapy provides superior outcome in patients with low‐risk disease. For intermediate‐risk disease, the combination of EBRT and brachytherapy appears equivalent to brachytherapy alone. For high‐risk patients, combination therapies involving EBRT and brachytherapy plus or minus androgen deprivation therapy appear superior to more localized treatments such as seed implant alone, surgery alone or EBRT. It is anticipated that the study will assist physicians and patients in selecting treatment for men with newly diagnosed prostate cancer.

show abstract

Section: Resultsmentioning

confidence: 99%

Comparative analysis of prostate‐specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group

Billiet²,

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Most of the other studies reported in Table 3 were smaller, some with as few as 110 patients (8). Nevertheless, as Table 3 shows, the results of these studies tend to converge, with 5-year BRFS rates ranging from a low of 86.9% (8) to a high of 98% (28).…”

Section: Discussionmentioning

confidence: 96%

Permanent seed brachytherapy for clinically localized prostate cancer: Long-term outcomes in a 700 patient cohort

et al. 2015

View full text Add to dashboard Cite

“…The first clinical tracer for imaging PSMA was based on the murine anti-PSMA antibody 7E11, binding to an epitope on the intracellular domain of PSMA. The 111 In-labeled version of 7E11, 111 In-capromab, commonly known as ProstaScint (Cytogen Corp.), was approved by the Food and Drug Administration in 1997 for detection of soft-tissue metastases and recurrence of PCa (7). Its use for staging primary PCa is suboptimal, with an average sensitivity and specificity of 60% and 70%, respectively (8).…”

mentioning

confidence: 99%

A Novel ¹¹¹In-Labeled Anti–Prostate-Specific Membrane Antigen Nanobody for Targeted SPECT/CT Imaging of Prostate Cancer

et al. 2015

View full text Add to dashboard Cite

Ten-Year Outcomes: The Clinical Utility of Single Photon Emission Computed Tomography/Computed Tomography Capromab Pendetide (Prostascint) in a Cohort Diagnosed With Localized Prostate Cancer

Cited by 30 publications

References 23 publications

Comparative analysis of prostate‐specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group

Comparative analysis of prostate‐specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group

Permanent seed brachytherapy for clinically localized prostate cancer: Long-term outcomes in a 700 patient cohort

A Novel ¹¹¹In-Labeled Anti–Prostate-Specific Membrane Antigen Nanobody for Targeted SPECT/CT Imaging of Prostate Cancer

Contact Info

Product

Resources

About

Ten-Year Outcomes: The Clinical Utility of Single Photon Emission Computed Tomography/Computed Tomography Capromab Pendetide (Prostascint) in a Cohort Diagnosed With Localized Prostate Cancer

Cited by 30 publications

References 23 publications

Comparative analysis of prostate‐specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group

Comparative analysis of prostate‐specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group

Permanent seed brachytherapy for clinically localized prostate cancer: Long-term outcomes in a 700 patient cohort

A Novel 111In-Labeled Anti–Prostate-Specific Membrane Antigen Nanobody for Targeted SPECT/CT Imaging of Prostate Cancer

Contact Info

Product

Resources

About

A Novel ¹¹¹In-Labeled Anti–Prostate-Specific Membrane Antigen Nanobody for Targeted SPECT/CT Imaging of Prostate Cancer